Literature DB >> 21229250

Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma.

Joana Heinzelmann1, Brenda Henning, Jimsgene Sanjmyatav, Nicole Posorski, Thomas Steiner, Heiko Wunderlich, Mieczyslaw R Gajda, Kerstin Junker.   

Abstract

PURPOSE: MicroRNAs (miRNAs) play an important role as regulators of gene expression in tumourigenesis by controlling many biological processes in growth, development, differentiation and apoptosis. Previous studies have shown an altered expression of specific miRNAs in clear cell renal cell carcinoma (ccRCC). But the function in cancerogenesis and metastasis in this tumour type is almost unknown. We aimed at identifying specific miRNA expression patterns that are associated with metastasis and prognosis in ccRCC patients.
METHODS: MiRNA of 30 human ccRCC including ten non-metastatic tumours, four tumours with metastasis after 3 years or later and four tumours with primary metastasis was isolated. We analysed the miRNA expression by using microarrays and qRT-PCR.
RESULTS: We detected a miRNA signature that distinguishes between metastatic and non-metastatic ccRCC, including miR-451, miR-221, miR-30a, miR-10b and miR-29a. Furthermore, we identified a group of 12 miRNAs, such as let-7 family, miR-30c, miR-26a, which are decreased in highly aggressive primary metastatic tumours. We found also correlations between expression levels of specific miRNAs with progression-free survival and overall survival.
CONCLUSION: Our findings suggest that specific miRNAs are involved in metastasis and have an impact on the progression of the ccRCC. Furthermore, we identified specific miRNAs characterising very aggressive tumours with early metastasis. In addition, we determined candidate markers associated with survival of the patients. Thus, it seems possible to use miRNAs for prediction of progression to distant metastasis and prognosis analysing the primary tumour.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21229250     DOI: 10.1007/s00345-010-0633-4

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  21 in total

1.  A molecular signature of metastasis in primary solid tumors.

Authors:  Sridhar Ramaswamy; Ken N Ross; Eric S Lander; Todd R Golub
Journal:  Nat Genet       Date:  2002-12-09       Impact factor: 38.330

2.  Prognostic factors in renal cell carcinoma.

Authors:  Börje Ljungberg
Journal:  Urologe A       Date:  2004-09       Impact factor: 0.639

3.  Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b.

Authors:  Gary K Scott; Andrei Goga; Dipa Bhaumik; Crystal E Berger; Christopher S Sullivan; Christopher C Benz
Journal:  J Biol Chem       Date:  2006-11-16       Impact factor: 5.157

4.  Morphological classification of renal cancer.

Authors:  S Störkel; E van den Berg
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

5.  Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics.

Authors:  W Thoenes; S Störkel; H J Rumpelt
Journal:  Pathol Res Pract       Date:  1986-05       Impact factor: 3.250

6.  MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B.

Authors:  Muller Fabbri; Ramiro Garzon; Amelia Cimmino; Zhongfa Liu; Nicola Zanesi; Elisa Callegari; Shujun Liu; Hansjuerg Alder; Stefan Costinean; Cecilia Fernandez-Cymering; Stefano Volinia; Gulnur Guler; Carl D Morrison; Kenneth K Chan; Guido Marcucci; George A Calin; Kay Huebner; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-21       Impact factor: 11.205

7.  Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival.

Authors:  Junichi Takamizawa; Hiroyuki Konishi; Kiyoshi Yanagisawa; Shuta Tomida; Hirotaka Osada; Hideki Endoh; Tomoko Harano; Yasushi Yatabe; Masato Nagino; Yuji Nimura; Tetsuya Mitsudomi; Takashi Takahashi
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

8.  Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis.

Authors:  Tsz-Fung F Chow; Youssef M Youssef; Evi Lianidou; Alexander D Romaschin; R John Honey; Robert Stewart; Kenneth T Pace; George M Yousef
Journal:  Clin Biochem       Date:  2009-07-29       Impact factor: 3.281

9.  Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7.

Authors:  Surabhi Dangi-Garimella; Jieun Yun; Eva M Eves; Martin Newman; Stefan J Erkeland; Scott M Hammond; Andy J Minn; Marsha Rich Rosner
Journal:  EMBO J       Date:  2009-01-15       Impact factor: 11.598

10.  Identification of a microRNA panel for clear-cell kidney cancer.

Authors:  David Juan; Gabriela Alexe; Travis Antes; Huiqing Liu; Anant Madabhushi; Charles Delisi; Shridhar Ganesan; Gyan Bhanot; Louis S Liou
Journal:  Urology       Date:  2009-12-29       Impact factor: 2.649

View more
  92 in total

Review 1.  MicroRNAs: potential regulators of renal development genes that contribute to CAKUT.

Authors:  April K Marrone; Jacqueline Ho
Journal:  Pediatr Nephrol       Date:  2013-09-03       Impact factor: 3.714

Review 2.  Deregulation of microRNA expression in thyroid neoplasias.

Authors:  Pierlorenzo Pallante; Sabrina Battista; Giovanna Maria Pierantoni; Alfredo Fusco
Journal:  Nat Rev Endocrinol       Date:  2013-11-19       Impact factor: 43.330

3.  Down-regulation of miR-29c in human bladder cancer and the inhibition of proliferation in T24 cell via PI3K-AKT pathway.

Authors:  Yanru Fan; Xuedong Song; Hongfei Du; Chunli Luo; Xiaorong Wang; Xue Yang; Yin Wang; Xiaohou Wu
Journal:  Med Oncol       Date:  2014-06-22       Impact factor: 3.064

4.  MicroRNA-30c serves as an independent biochemical recurrence predictor and potential tumor suppressor for prostate cancer.

Authors:  Xiao-hui Ling; Zhao-dong Han; Dan Xia; Hui-chan He; Fu-neng Jiang; Zhuo-yuan Lin; Xin Fu; Ye-han Deng; Qi-shan Dai; Chao Cai; Jia-hong Chen; Yu-xiang Liang; Wei-de Zhong; Chin-lee Wu
Journal:  Mol Biol Rep       Date:  2014-01-23       Impact factor: 2.316

Review 5.  The miR-10 microRNA precursor family.

Authors:  Disa Tehler; Nina Molin Høyland-Kroghsbo; Anders H Lund
Journal:  RNA Biol       Date:  2011-09-01       Impact factor: 4.652

Review 6.  [Epigenetic regulation of urological tumors. Importance for prognosis and metastasis].

Authors:  J Heinzelmann; B Stubendorff; V Jung; S Baumgart; S Hölters; G Unteregger; J Grimm; J Linxweiler; M Janssen; C-H Ohlmann; M Saar; S Siemer; M Stöckle; K Junker
Journal:  Urologe A       Date:  2015-06       Impact factor: 0.639

7.  Elevated miR-182-5p Associates with Renal Cancer Cell Mitotic Arrest through Diminished MALAT-1 Expression.

Authors:  Priyanka Kulkarni; Pritha Dasgupta; Nadeem S Bhat; Varahram Shahryari; Marisa Shiina; Yutaka Hashimoto; Shahana Majid; Guoren Deng; Sharanjot Saini; Z Laura Tabatabai; Soichiro Yamamura; Yuichiro Tanaka; Rajvir Dahiya
Journal:  Mol Cancer Res       Date:  2018-07-23       Impact factor: 5.852

8.  Down-regulation of miRNA-30a in human plasma is a novel marker for breast cancer.

Authors:  Rui-chao Zeng; Wei Zhang; Xing-qiang Yan; Zhi-qiang Ye; En-dong Chen; Du-ping Huang; Xiao-hua Zhang; Guan-li Huang
Journal:  Med Oncol       Date:  2013-02-07       Impact factor: 3.064

9.  Deep sequencing reveals microRNAs predictive of antiangiogenic drug response.

Authors:  Jesús García-Donas; Benoit Beuselinck; Lucía Inglada-Pérez; Osvaldo Graña; Patrick Schöffski; Agnieszka Wozniak; Oliver Bechter; Maria Apellániz-Ruiz; Luis Javier Leandro-García; Emilio Esteban; Daniel E Castellano; Aranzazu González Del Alba; Miguel Angel Climent; Susana Hernando; José Angel Arranz; Manuel Morente; David G Pisano; Mercedes Robledo; Cristina Rodriguez-Antona
Journal:  JCI Insight       Date:  2016-07-07

10.  Tumor suppressive miR-509-5p contributes to cell migration, proliferation and antiapoptosis in renal cell carcinoma.

Authors:  W-B Zhang; Z-Q Pan; Q-S Yang; X-M Zheng
Journal:  Ir J Med Sci       Date:  2013-04-26       Impact factor: 1.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.